European CRO Selects OmniComm eClinical Solutions for Phase III Study
Ft. Lauderdale, FL-based OmniComm Systems, Inc. (OTC: OMCM.OB), announced that it has been selected by a leading European-based CRO to provide eClinical solutions for a pivotal Phase III study in rheumatoid arthritis (RA). This RA study is expected to last 48 months and enroll close to 300 patients in 20 sites located in Europe.
“We are very excited to be working again with this leading CRO on this pivotal study,” commented Stephen Johnson, OmniComm’s COO. “We appreciate their ongoing trust in us and will continue to deliver superior products and services to them. We are also very excited about our continued expansion into the European marketplace. We have recently opened up another office in the United Kingdom, OmniComm Ltd., which will allow us to broaden our service and support offering even further.” OmniComm Systems also has international offices in Bonn, Germany and Tula, Russia.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
